NASDAQ:PRTA Prothena (PRTA) Stock Price, News & Analysis $8.40 +0.05 (+0.60%) Closing price 04:00 PM EasternExtended Trading$8.40 -0.01 (-0.06%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Prothena Stock (NASDAQ:PRTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prothena alerts:Sign Up Key Stats Today's Range$8.17▼$8.4950-Day Range$7.89▼$9.1052-Week Range$7.70▼$11.80Volume566,979 shsAverage Volume508,244 shsMarket Capitalization$431.34 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company Overview Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease. These are candidates in development, not approved medicines. Prothena was established in 2012 as a spinout from Elan Corporation and operates in Ireland and the United States. Its research and development programs are supported by collaborations with pharmaceutical companies, including Roche.AI Generated. May Contain Errors. Read More Prothena Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScorePRTA MarketRank™: 2.99004907306 of 5 starsProthena scored higher than 60% of companies evaluated by MarketBeat, and ranked 723rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingProthena has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialProthena has a consensus price target of $20.00, representing about 140.2% upside from its current price of $8.33.Amount of Analyst CoverageProthena has only been the subject of 2 research reports in the past 90 days.Read more about Prothena's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from $0.06 to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioProthena has a PEG Ratio of 4.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProthena has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.19% of the float of Prothena has been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 15.69, which indicates bearish sentiment.Change versus previous monthShort interest in Prothena has recently decreased by 0.36%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.58 News SentimentProthena has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Prothena this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows1 people have added Prothena to their MarketBeat watchlist in the last 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $10,253,550.00 in company stock, which represents 2.3986% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,253,550.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prothena's insider trading history. Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTA Stock News HeadlinesInsider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Buys $1,194,200.00 in StockNovember 13, 2026 | americanbankingnews.comHC Wainwright Has Positive View of Prothena FY2026 EarningsNovember 12, 2026 | americanbankingnews.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 19 at 1:00 AM | Paradigm Press (Ad)Insider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Purchases $1,194,200.00 in StockNovember 11, 2026 | insidertrades.comProthena: Q3 earnings snapshotNovember 5, 2026 | msn.comProthena consensus price target lowered by 17.06% to $18.10November 3, 2026 | msn.comProthena to Report Third Quarter 2026 Financial Results on November 5October 30, 2026 | finance.yahoo.comInsider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Acquires $403,500.00 in StockOctober 27, 2026 | insidertrades.comSee More Headlines PRTA Stock Analysis - Frequently Asked Questions How have PRTA shares performed this year? Prothena's stock was trading at $9.55 at the start of the year. Since then, PRTA stock has decreased by 12.8% and is now trading at $8.3250. How were Prothena's earnings last quarter? Prothena Corporation plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.09. The biotechnology company earned $620 thousand during the quarter, compared to analyst estimates of $9.58 million. Prothena had a negative trailing twelve-month return on equity of 9.98% and a negative net margin of 45.44%. Who are Prothena's major shareholders? Top institutional shareholders of Prothena include State Street Corp (3.59%), Goldman Sachs Group Inc. (1.75%), Focused Wealth Management Inc (0.38%) and Pinnacle Associates Ltd. (0.12%). Insiders that own company stock include William P Scully, Anne Evans Kingston, Michael John Isaacs and Karin L Walker. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Tesla (TSLA), Alibaba Group (BABA), NVIDIA (NVDA), GE Aerospace (GE), Plug Power (PLUG), Bristol Myers Squibb (BMY) and ExxonMobil (XOM). Company Calendar Last Earnings11/05/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, PRTA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRTA CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees67Year Founded2012Price Target and Rating Average Price Target for Prothena$20.00 High Price Target$30.00 Low Price Target$12.00 Potential Upside/Downside+138.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth4.33Net Income-$244.09 million Net Margins-45.44% Pretax Margin-45.41% Return on Equity-9.98% Return on Assets-9.08% Debt Debt-to-Equity RatioN/A Current Ratio23.95 Quick Ratio23.95 Sales & Book Value Annual Sales$52.74 million Price / Sales8.18 Cash FlowN/A Price / Cash FlowN/A Book Value$5.24 per share Price / Book1.60Miscellaneous Outstanding Shares51,350,000Free Float46,010,000Market Cap$431.34 million OptionableOptionable Beta-0.20 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PRTA) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.